We looked inside some of the tweets by @ElsTorreele and here's what we found interesting.
Inside 100 Tweets
Check out our new cool site: http://www.tumgir.com
Last Seen Profiles@HKinoa@hikarinn811@kuhlayer@Emylokman@pablengue@Luna_Libros@uvicnews@yaniv_raz@graceychou@Linemanoutfitt@ttman100@SolAltamirano_@rosiejay@Dansamjul@rayhana3x@AlarikSandrup
These people have no shame! Bor does @Twitter in promoting this predatory behavior
It's enough to make you weep: A rare & chilling account from the field of how the #Ebola response in Butembo & Katwa has come under attack from the very people it's trying to save. I don't see how this gets better. h/t to @crof.
Un médicament sans brevet pour vaincre enfin la maladie du sommeil @DNDi
A human-rights approach is essential to end the global TB epidemic @paimadhu
⚠ Overcrowded ⚠ Dirty ⚠ Unsafe These are the conditions that people in the Greek island ‘hotspots’ are forced to endure due to the EU's harmful policy of containment. #LetThemOut http://bit.ly/2CpNe8d
Snakebite: a neglected but perfectly curable problem. “Experts and campaigners blame weak production capacity, feeble policy and oversight, high prices and general lack of concern for people in poor, remote areas of the world.” @julienpotet
IP incentives reward R&D with commercial potential, not necessarily therapeutic advances. We need to re-think how to award useful medical innovation like better use of existing products independent from market potential
In general, optimizing the use of existing drugs or repurposing drugs for new indications tends to be neglected unless new patents can be secured. But what is patentable under IP law is totally disconnected from what provides medical benefit
Another example to show that commercial incentives are ill-suited to stimulate patient-centered medical innovation, especially if that translates into shorter treatments, and thus lower sales.
For 50 years, we have treated Chagas disease with a 2-month course of benznidazole. Researchers now find that 2 works as well - while much better tolerated by patients. Important medical innovation is not just what can be patented @DNDi
The U.S. patent system incentivizes #pharma to overpatent every little tweak to a medicine, driving up prices and blocking access for patients who need them most. Our report breaks it down: http://i-mak.org/overpatented
Doctors Without Borders blasts coalition working on vaccine development #TellCEPI #Access2Meds https://www.statnews.com/pharmalot/2019/03/15/doctors-without-borders-blasts-coalition-working-on-vaccine-development/ … via @statnews
What a crock of you-know-what. The Alliance for Patient Access claims to be a network of doctors that advocates for patients. Actually it's an alliance of pharma companies fighting reforms, run by DC lobbyist & committing tax fraud in claiming 501c3 status
Shameful: Public research university #UCLA goes to court in India to stop generic production of cancer drug they helped develop, preventing Indian patients to have affordable access. Medical innovation is worthless if people cannot access it @uaem
When diagnosis and treatment is big business: Healthcare is in a tailspin as the rush to offer technology and services turns otherwise healthy people into concerned patients by identifying disease that is not destined to cause them harm.
Conservative leadership candidates now openly competing to take from the poor and give to the rich. Disgusting.
On the third anniversary of the signing of the #EU-Turkey deal, we are calling on European leaders to take action to end the harmful policy of containment on the Greek island ‘hotspots’.
'@CEPIvaccines needs to stand strong in the face of industry pressure, adopting a policy to make sure that patient access is a priority’ READ our letter to editor published in @Telegraph on why @CEPIvaccines needs a strong access policy. FULL LETTER 👇 https://bit.ly/2JnDOzN
To eliminate HIV the price of medications to treat and prevent it must sharply reduce (currently $10.000s ppy). But so far the administration has shown no appetite for using existing laws to override the patents of these drugs and produce them at cost